At Sichuan Qingmu Pharmaceutical Co., Ltd., we understand that the foundation of exceptional healthcare products lies in the quality of their active pharmaceutical ingredients (APIs). With over a decade of unwavering commitment to innovation and excellence, Qingmu Pharma has established itself as a leading provider of APIs, serving the global healthcare market with the highest standards of efficacy, safety, and environmental sustainability.
A Legacy of Excellence and Trust
Founded in May 2011, Qingmu pharmaceutical company has built a reputation of trust and expertise over 12 years, operating as a wholly-owned subsidiary of Chengdu Easton Biopharmaceuticals Co., Ltd. Our dedication to quality has positioned us as an innovation-driven pharmaceutical company with a strategic focus on the regulated market.
Innovative R&D: Pioneering the Future of Pharmaceuticals
Our R&D platform is at the heart of our operations, embracing the concept of "Green Chemistry" to develop sustainable and efficient pharmaceutical solutions. We've pioneered key technical platforms, including asymmetric synthesis, transition metal catalysis, microchannel production, and enzyme catalysis, to ensure our APIs not only meet but exceed industry standards.
Comprehensive CDMO Services: From Concept to Commercialization
Qingmu pharmaceutical company's CDMO/CMO services offer an integrated approach to small molecule chemical drug development. Our scope of services encompasses everything from early-stage research to commercial-scale manufacturing, powered by our formidable technical capabilities and a collaborative spirit with our partners.
State-of-the-Art Manufacturing: Quality at the Forefront
Our manufacturing system is built on a policy of people-oriented practices and sustainable development. We prioritize health, safety, energy conservation, environmental protection, and pollution prevention, ensuring full participation in our pursuit of sustainable development.